Effect of testosterone replacement therapy on Vitamin D and FGF-23 levels in congenital hypogonadism
Endokrynologia Polska, cilt.68, sa.3, ss.311-316, 2017 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 68 Sayı: 3
- Basım Tarihi: 2017
- Doi Numarası: 10.5603/ep.a2017.0009
- Dergi Adı: Endokrynologia Polska
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.311-316
- Anahtar Kelimeler: hypogonadism, vitamin D, fibroblast growth factor-23, asymmetric dimethyl arginine
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: Patients with hypogonadism are at increased risk of cardiac and metabolic diseases and osteoporosis. Vitamin D and fibroblast growth factor-23 (FGF-23) play a role in the regulation of bone mineral metabolism and endothelial functions. Low Vitamin D levels are reported in hypogonadism, while there is no data about the effect of testosterone replacement therapy (TRT). We investigated the effect of TRT on Vitamin D and FGF-23 levels along with endothelial functions and insulin resistance in hypogonadal patients. Material and methods: Patients with congenital hypogonadotrophic hypogonadism (CHH) (n = 32, age 20.6 ± 1.58 years) were enrolled. TRT was implemented in transdermal form. The demographic parameters, FGF-23, 25(OH)D3, asymmetric dimethylarginine (ADMA), and homeostatic model assessment of insulin resistance (HOMA-IR) levels, were measured both before and after TRT. Results: After a follow-up period of 3.63 ± 1.33 months, ADMA and FGF-23 levels were significantly increased (p = 0.03 and p = 0.005 respectively), while 25(OH)D3 and HOMA-IR index were not significantly changed. The body mass index and waist circumference levels of the patients were also increased (p < 0.001 and p = 0.02) along with a significant decrease in the HDL cholesterol levels (p = 0.006). Conclusions: The results show that short-term TRT increases plasma FGF-23 and ADMA levels but does not alter the Vitamin D levels in young, treatment naive patients with CHH. Whether this is an early implication of TRT-related adverse effects in this very young and treatment naïve population of CHH is not clear. Future prospective studies are required to find out the long-term effects of TRT on cardiometabolic morbidity and mortality in this specific population.